Polymorphisms in the glutathione S-transferase M1, T 1, and P1 genes and prostate cancer prognosis

Prostate

Volumn 66, Issue 14, 2006, Pages 1535-1541

  Agalliu, Ilir ^a   Lin, Daniel W ^a,b   Salinas, Claudia A ^a,c   Feng, Ziding ^a   Stanford, Janet L ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Biomarker; Genetic polymorphisms; Gluthatione S transferase; Prostate cancer mortality; Prostate cancer progression

Indexed keywords

GLUTATHIONE TRANSFERASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER MORTALITY; COHORT ANALYSIS; CONTROLLED STUDY; GENE; GENOTYPE; GST GENE; GSTM1 GENE; GSTP1 GENE; GSTT1 GENE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

COHORT STUDIES; FOLLOW-UP STUDIES; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; VARIATION (GENETICS);

EID: 33749055943     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20491     Document Type: Article

References (21)

1. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004;172(5 Pt 2):S6-11.
2. Lucia MS, Torkko KC. Inflammation as a target for prostate cancer chemoprevention: Pathological and laboratory rationale. J Urol 2004;171(2 Pt 2):S30-S34.
3. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG. Prostate carcinogenesis and inflammation: Emerging insights. Carcinogenesis 2005;26(7):1170-1181.
4. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51-88.
5. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995;30:445-600.
6. Di Ilio C, Aceto A, Bucciarelli T, Angelucci S, Felaco M, Grilli A, Federici G. Glutathione transferase isoenzymes from human prostate. Biochem J 1990;271:481-485.
7. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733-743.
8. Zimniak P, Nanduri B, Pikula S, et al. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymatic properties. Eur J Biochem 1994;224:893-899.
9. Hu X, Xia H, Srivastava SK, Herzog C, Awasthi YC, Ji X, Zimniak P, Singh SV. Activity of four allelic forms of glutathione S-Transferase hGSTP1-1 for diol epoxides of polycyclic aromatic hydrocarbons. Biochem Biophys Res Commun 1997;238:397-402.
10. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733-11737.
11. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-1986.
12. Stanford JL, Wicklund KG, McKnight B, Daling JR, Brawer MK. Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999;8:881-886.
13. Sambrook J, Fritsch EF, Maniatis T. Isolation of high-molecular weight DNA from mammalian cells. In: Nolan C, editor. Molecular cloning: A laboratory manual, Vol. 2. Plainview, NY: Cold Spring Harbor Press; 1989. pp 9.16-9.19.
14. Cox DR. Regression models with life-tables (with discussion). J Roy Statistic Soc: Series B 1972;34:187-220.
15. Robins JM, Rotnitzky A, Zhao LP. Estimation of regression coefficients when some regressors are not always observed. J Am Stat Assoc 1994;89:846-866.
16. Hosmer DW, Lemeshow S. Applied survival analysis: Regression modeling to time to event data. New York, NY: Wiley, John & Sons, Incorporated; 1999.
17. Freeman VL, Durazo-Arvizu R, Keys LC, Johnson MP, Schafernak K, Patel VK. Racial differences in survival among men with prostate cancer and comorbidity at time of diagnosis. Am J Public Health 2004;94:803-808.
18. Godley PA, Schenck AP, Amamoo MA, Schoenbach VJ, Peacock S, Manning M, Symons M, Talcott JA. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst 2003;95(22):1702-1710.
19. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C, Breskvar K, Brockmoller J, Cascorbi I, Clapper ML, Coutelle C, Daly A, Dell'Omo M, Dolzan V, Dresler CM, Fryer A, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang D, Kihara M, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, van Lieshout EM, London S, Manni JJ, Maugard CM, Morita S, Nazar-Stewart V, Noda K, Oda Y, Pari FF, Pastorelli R, Persson I, Peters WH, Rannug A, Rebbeck T, Risch A, Roelandt L, Romkes M, Ryberg D, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnet D, Strange RC, Stucker I, Sugimura H, To-Figueras J, Vineis P, Yu MC, Taioli E. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001;10:1239-1248.
20. Enokida H, Shiina H, Urakami S, Terashima M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Igawa M, Dahiya R. Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma. Cancer 2006;106(1):79-86.
21. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005;65(10):4218-4227.